Investors Face Deadline in Securities Fraud Lawsuit Against ADMA Biologics

The legal action, captioned Mazzarino v. ADMA Biologics, Inc., follows a March 2026 report by Culper Research. The report accused the company of channel stuffing—artificially inflating revenue by inducing distributors to stock excess product through rebates and extended payment terms. Following these allegations, ADMA Biologics shares dropped 29.1% over two trading days, closing at $9.63 on March 25, 2026.

Kessler Topaz Meltzer & Check, LLP is now advising affected shareholders of their right to seek lead plaintiff status. The complaint asserts that the company failed to disclose related-party transactions and maintained inadequate internal financial oversight. Investors who suffered losses during the specified period may contact attorney Jonathan Naji to discuss recovery options. Participation as a lead plaintiff is voluntary, and investors may also choose to remain absent class members without affecting their ability to share in a potential recovery.